TACSTD2 and adenocarcinoma: compared different NSCLC subtypes and found that TROP2 protein levels were significantly increased in 64% (172/270) of adenocarcinomas, 75% (150/201) of squamous cell carcinomas, and 18% (21/115) of high-grade neuroendocrine tumors (HGNETs) (41).